北京大学学报(医学版) ›› 2025, Vol. 57 ›› Issue (5): 996-1001. doi: 10.19723/j.issn.1671-167X.2025.05.027

• 论著 • 上一篇    下一篇

姑息治疗对晚期癌症患者药物使用和医疗资源利用的影响

陈定一1, 杜浩鑫1, 张逸晨1, 王闫飞2, 刘巍2, 焦园园2, 史录文1,3, 管晓东1,3, 卢新璞2,*()   

  1. 1. 北京大学药学院药事管理与临床药学系, 北京 100191
    2. 北京大学肿瘤医院暨北京市肿瘤防治研究所, 恶性肿瘤发病机制及转化研究教育部重点实验室, 北京 100142
    3. 北京大学医药管理国际研究中心, 北京 100191
  • 收稿日期:2023-02-20 出版日期:2025-10-18 发布日期:2025-09-05
  • 通讯作者: 卢新璞

Impact of palliative care on medication use and medical utilization in patients with advanced cancer

Dingyi CHEN1, Haoxin DU1, Yichen ZHANG1, Yanfei WANG2, Wei LIU2, Yuanyuan JIAO2, Luwen SHI1,3, Xiaodong GUAN1,3, Xinpu LU2,*()   

  1. 1. Department of Pharmacy Administration and Clinical Pharmacy, Peking University School of Pharmaceutical sciences, Beijing 100191, China
    2. Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China
    3. International Research Center for Medicinal Administration, Peking University, Beijing 100191, China
  • Received:2023-02-20 Online:2025-10-18 Published:2025-09-05
  • Contact: Xinpu LU

RICH HTML

  

摘要: 目的: 评价姑息治疗对晚期癌症患者药物使用、医疗服务利用及医疗费用的影响。方法: 基于2018—2020年北京大学肿瘤医院患者就诊记录,采用广义精确匹配法构建包括姑息治疗与常规治疗两组患者队列,分别选取阿片类镇痛药物月均使用量、住院率、重症监护室(intensive care unit,ICU)率、手术率、月均总费用等指标评价药物使用、医疗服务利用与医疗费用,采用卡方检验和Wilcoxon符号秩检验比较暴露前后两组患者结局指标差异及姑息治疗组患者结局指标变化,采用倍差法测算姑息治疗对患者各结局指标的净影响值。结果: 最终纳入180例姑息治疗组患者与3 101例常规治疗组患者,组间匹配效果良好(L1 < 0.1)。暴露前后,姑息治疗组阿片类药物月均使用量均显著高于常规治疗组(暴露前:0.3 DDD/人月vs. 0.1 DDD/人月,P < 0.01;暴露后:0.7 DDD/人月vs. 0.1 DDD/人月,P < 0.01;DDD为限定日剂量,defined daily dose),姑息治疗显著增加了患者的阿片类药物月均使用量(增加0.3 DDD/人月,P < 0.01)。暴露后,姑息治疗组住院率和手术率均显著低于常规治疗组(48.9% vs. 74.3%,3.9% vs. 8.8%,P均 < 0.01),两组患者的ICU率相似(1.1% vs. 1.6%,P=0.634)。姑息治疗显著降低了患者的住院率、ICU率和手术率,分别降低25.6%、4.9%和14.5%(P均 < 0.01)。暴露前后,姑息治疗组月均总费用均略高于常规治疗组(暴露前:20 092.3元vs. 19 132.8元,P=0.725;暴露后:9 719.8元vs. 8 818.8元,P=0.165),但姑息治疗对患者的月均总费用无显著影响(增加2 208.8元,P=0.316)。结论: 姑息治疗可以增加晚期癌症患者阿片类药物使用量,降低住院率、ICU率和手术率,而对患者医疗费用无显著影响。

关键词: 姑息疗法, 肿瘤, 阿片, 药物利用, 医疗服务利用, 医疗费用

Abstract: Objective: To evaluate the effect of palliative care on drug use, medical service utilization and medical expenditure of patients with advanced cancer. Methods: A cohort of patients including pal-liative care and standard care was constructed using the medical records of the patients in Peking University Cancer Hospital from 2018 to 2020, and coarsened exact matching was used to match the two groups of patients. The average monthly opioid consumption, hospitalization rate, intensive care unit (ICU) rate and operation rate, and the average monthly total cost were selected to evaluate drug use, medical service utilization and medical expenditure. Chi-square test and Wilcoxon signed rank test were used to compare the differences between the two groups before and after exposure and the change in the palliative care group. The net impact of palliative care on the patients was calculated using the difference-in-differences analysis. Results: In this study, 180 patients in the palliative care group and 3 101 patients in the stan-dard care group were finally included in the matching, and the matching effect of the two groups was good (L1 < 0.1). Before and after exposure, the average monthly opioid consumption in the palliative care group was significantly higher than that in the standard care group (Before exposure: 0.3 DDD/person-month vs. 0.1 DDD/person-month, P < 0.01; After exposure: 0.7 DDD/person-month vs. 0.1 DDD/person-month, P < 0.01; DDD refers to defined daily dose), palliative care significantly increased the average monthly opioid consumption in the patients (0.3 DDD/person-month, P < 0.01). The hospitalization rate (48.9% vs. 74.3%, P < 0.01) and operation rate (3.9% vs. 8.8%, P < 0.01) of the patients in palliative care group were significantly lower than those in standard care group, and the ICU rate became similar between the two groups (1.1% vs. 1.6%, P=0.634). Palliative care significantly reduced the patients ' hospitalization rate (-25.6%, P < 0.01), ICU rate (-4.9%, P < 0.01) and operation rate (-14.5%, P < 0.01). Before and after exposure, the average monthly total costs of pal-liative care group were slightly higher than those of standard care group (Before exposure: 20 092.3 yuan vs. 19 132.8 yuan, P=0.725; After exposure: 9 719.8 yuan vs. 8 818.8 yuan, P=0.165). Palliative care increased the average monthly total cost by 2 208.8 yuan, but it was not statistically significant (P=0.316). Conclusion: Palliative care can increase the opioid consumption in advanced cancer patients, reduce the rates of hospitalization, ICU and surgery, but has no significant effect on medical expenditure.

Key words: Palliative care, Neoplasm, Opium, Drug utilization, Medical service utilization, Medical expenditure

中图分类号: 

  • R730.5

图1

患者纳入、排除、分组及匹配流程图"

图2

研究中各时间点与时间段"

表1

姑息治疗组与常规治疗组患者的基本特征"

Items Palliative care group (n=180) Standard care group (n=3 101) L1
Sex <0.01
    Female 55 (30.6) 1 198 (38.6)
    Male 125 (69.4) 1 903 (61.4)
Age/years 0.013
    18-44 8 (4.4) 54 (1.7)
    45-64 75 (41.8) 1 308 (42.2)
    ≥65 97 (53.9) 1 739 (56.1)
Location of medical insurance 0.046
    Local 42 (23.3) 578 (18.6)
    Non-local 138 (76.7) 2 523 (81.4)
Year of diagnosis 0.072
    2011-2015 13 (7.2) 30 (1.0)
    2016-2020 167 (92.8) 3 071 (99.0)
Cancer site 0.044
    Digestive system 80 (44.4) 984 (31.7)
    Respiratory system 19 (10.6) 242 (7.8)
    Genital system 1 (0.6) 3 (0.1)
    Hematologic system 1 (0.6) 259 (8.4)
    Breast 5 (2.8) 13 (0.4)
    Head and neck 6 (3.3) 7 (0.2)
    Other sites 6 (3.3) 9 (0.3)
    Not specified 62 (34.4) 1 584 (51.1)

表2

暴露前后两组患者各结局指标对比"

Outcomes Before exposure After exposure
Palliative care group Standard care group P Palliative care group Standard care group P
Drug use
  Average monthly opioid consumption/DDD per person-month 0.3 0.1 <0.01 0.7* 0.1 <0.01
Medical service utilization
  Hospital rate/% 100.0 99.8 0.555 48.9* 74.3 <0.01
  ICU rate/% 6.7 2.3 <0.01 1.1* 1.6 0.634
  Operation rate/% 25.6 15.1 <0.01 3.9* 8.8 <0.01
Medical expenditure
  Average monthly total cost/yuan 20 092.3 19 132.8 0.725 9 719.8 8 818.8 0.165

表3

姑息治疗对患者各结局指标的净影响值"

Outcomes Net effect value |t| P
Drug use
    Average monthly opioid consumption/DDD per person-month 0.3 4.48 <0.01
Medical service utilization
    Hospital rate/% -25.6 4.53 <0.01
    ICU rate/% -4.9 3.17 <0.01
    Operation rate/% -14.5 4.02 <0.01
Medical expenditure
    Average monthly total cost/yuan 2 208.8 1.00 0.316
1
WHO. Detail of Palliative Care[EB/OL]. (2020-08-05)[2022-05-01]. https://www.who.int/news-room/fact-sheets/detail/palliative-care.
2
刘佩, 蒲嘉泽, 黄雯. 晚期恶性肿瘤患者采用姑息治疗的临床效果[J]. 临床合理用药杂志, 2021, 14 (8): 169- 170.
3
赵杰. 安宁疗护和姑息治疗对直肠癌晚期患者临终期生活质量的影响[J]. 中国肛肠病杂志, 2022, 42 (3): 62- 63.
4
郭敏, 孟华, 张庆波. 姑息治疗老年恶性肿瘤患者的临床效果观察[J]. 中国社区医师, 2021, 37 (10): 15- 16.
5
Greer JA , Applebaum AJ , Jacobsen JC , et al. Understanding and addressing the role of coping in palliative care for patients with advanced cancer[J]. J Clin Oncol, 2020, 38 (9): 915-925, 198.

doi: 10.1200/JCO.19.00013
6
王茜, 林天华, 张仑. 晚期癌症患者的姑息护理研究进展分析[J]. 实用临床护理学电子杂志, 2018, 3 (15): 193- 198.
7
Triplett DP , LeBrett WG , Bryant AK , et al. Effect of palliative care on aggressiveness of end-of-life care among patients with advanced cancer[J]. J Oncol Pract, 2017, 13 (9): e760- e769.

doi: 10.1200/JOP.2017.020883
8
Smith CB , Phillips T , Smith TJ . Using the new ASCO clinical practice guideline for palliative care concurrent with oncology care using the TEAM approach[J]. Am Soc Clin Oncol Educ Book, 2017, 37, 714- 723.

doi: 10.1200/EDBK_175474
9
宁晓红. 中国缓和医疗的发展和思考[J]. 中国医学科学院学报, 2019, 41 (5): 723- 725.
10
张丽艳, 沈美玲. 积极养老视角下我国安宁疗护政策研究——基于2012-2019年政策文本分析[J]. 科学与管理, 2021, 41 (2): 49- 54.
11
Xu M , Zhou W , Yang L , et al. Effect of palliative care on the anxiety, depression and sleep quality in primary caregivers of elderly patients with terminal cancer[J]. Am J Transl Res, 2021, 13 (4): 3738- 3744.
12
Siddiqui ST , Xiao E , Patel S , et al. Impact of palliative care on interhospital transfers to the Intensive Care Unit[J]. J Crit Care Med (Targu Mures), 2022, 8 (2): 100- 106.

doi: 10.2478/jccm-2022-0009
13
Pelcovits A , Olszewski AJ , Decker D , et al. Impact of early pal-liative care on end-of-life outcomes in hematologic malignancies[J]. J Palliat Med, 2022, 25 (4): 556- 561.
14
Pottash M , McCamey D , Groninger H , et al. Palliative care consultation and effect on length of stay in a tertiary-level neurological intensive care unit[J]. Palliat Med Rep, 2020, 1 (1): 161- 165.

doi: 10.1089/pmr.2020.0051
15
Iacus SM , King G , Porro G . Causal inference without balance checking: Coarsened exact matching[J]. Polit Anal, 2012, 20 (1): 1- 24.

doi: 10.1093/pan/mpr013
16
Vallard A , Morisson S , Tinquaut F , et al. Drug management in end-of-life hospitalized palliative care cancer patients: The RHESO cohort study[J]. Oncology, 2019, 97 (4): 217- 227.

doi: 10.1159/000500783
17
Fredheim OM , Skurtveit S , Handal M , et al. A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years after diagnosis[J]. Pain, 2019, 160 (4): 852- 859.

doi: 10.1097/j.pain.0000000000001459
18
Gade G , Venohr I , Conner D , et al. Impact of an inpatient palliative care team: A randomized control trial[J]. J Palliat Med, 2008, 11 (2): 180- 190.

doi: 10.1089/jpm.2007.0055
19
Dimick JB , Ryan AM . Methods for evaluating changes in health care policy: The difference-in-differences approach[J]. JAMA, 2014, 312 (22): 2401- 2402.

doi: 10.1001/jama.2014.16153
20
van den Beuken-van Everdingen MH , Hochstenbach LM , Joosten EA , et al. Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis[J]. J Pain Symptom Manage, 2016, 51 (6): 1070- 1090.

doi: 10.1016/j.jpainsymman.2015.12.340
21
王薇. 北京市癌痛治疗现状调查分析及草乌甲素治疗轻中度癌痛的临床研究[D]. 北京: 中国中医科学院, 2019.
22
海峡两岸医药卫生交流协会全科医学分会. 姑息治疗与安宁疗护基本用药指南[J]. 中国全科医学, 2021, 24 (14): 1717- 1734.
23
NCCN. NCCN clinical practice guidelines in oncology: Palliative care[M/OL]. (2020-02-27)[2022-03-04]. https://www.nccn.org/professionals/physician_gls/pdf/palliative_enhanced.pdf.
24
Samuel D , Nevadunsky NS , Miller DT , et al. Opioid prescription by gynecologic oncologists: An analysis of Medicare part D claims[J]. Curr Probl Cancer, 2021, 45 (2): 100655.

doi: 10.1016/j.currproblcancer.2020.100655
25
Quinn KL , Shurrab M , Gitau K , et al. Association of receipt of palliative care interventions with health care use, quality of life, and symptom burden among adults with chronic noncancer illness: A systematic review and meta-analysis[J]. JAMA, 2020, 324 (14): 1439- 1450.

doi: 10.1001/jama.2020.14205
26
Mack JW , Cronin A , Keating NL , et al. Associations between end-of-life discussion characteristics and care received near death: A prospective cohort study[J]. J Clin Oncol, 2012, 30 (35): 4387- 4395.

doi: 10.1200/JCO.2012.43.6055
27
Obermeyer Z , Makar M , Abujaber S , et al. Association between the Medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer[J]. JAMA, 2014, 312 (18): 1888- 1896.

doi: 10.1001/jama.2014.14950
28
Higginson IJ , Bausewein C , Reilly CC , et al. An integrated pal-liative and respiratory care service for patients with advanced disease and refractory breathlessness: A randomised controlled trial[J]. Lancet Respir Med, 2014, 2 (12): 979- 987.

doi: 10.1016/S2213-2600(14)70226-7
29
Haukland EC , von Plessen C , Nieder C , et al. Adverse events in deceased hospitalised cancer patients as a measure of quality and safety in end-of-life cancer care[J]. BMC Palliat Care, 2020, 19 (1): 76.

doi: 10.1186/s12904-020-00579-0
30
杨晓燕. ICU危重患者机械通气后常见并发症护理[J]. 医药论坛杂志, 2009, 30 (10): 127- 128.
31
荆明远. 腹腔镜胃癌手术常见并发症及其防治对策[J]. 中国卫生标准管理, 2014, 5 (20): 120- 121.
32
舒芳芳, 包磊, 朱蓓, 等. 成人择期手术患者术前焦虑现状、恐惧焦点及影响因素的横断面调查研究[J]. 实用临床医药杂志, 2022, 26 (6): 72-76, 108.
33
Maley JH , Worsham CM , Landon BE , et al. Association between palliative care and end-of-life resource use for older adults hospitalized with septic shock[J]. Ann Am Thorac Soc, 2020, 17 (8): 974- 979.

doi: 10.1513/AnnalsATS.202001-038OC
[1] 季加孚, 韦静涛, 季科, 步召德. 胃癌诊疗的瓶颈与破局:迈向精准化与智能化融合的新纪元[J]. 北京大学学报(医学版), 2026, 58(2): 231-238.
[2] 高加勒, 张忠涛. 局部进展期直肠癌精准治疗现状与展望[J]. 北京大学学报(医学版), 2026, 58(2): 247-250.
[3] 王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报(医学版), 2026, 58(2): 251-256.
[4] 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报(医学版), 2026, 58(2): 257-265.
[5] 杜文, 章文博, 于尧, 刘硕, 苏惠裕, 胡耒豪, 唐祖南, 吴彬彰, 陈震, 李家琦, 王昊, 彭歆. 口腔颌面部肿瘤"数智化外科"诊疗流程探索与临床应用[J]. 北京大学学报(医学版), 2026, 58(2): 278-284.
[6] 王楠楠, 袁大晋, 朱昱冰, 丁磊. 结直肠癌根治术后肝转移风险多中心列线图预测模型的构建与验证[J]. 北京大学学报(医学版), 2026, 58(2): 290-300.
[7] 刘友东, 吕亚军, 陈杰, 臧明德, 潘宏达, 刘晓文, 陆俊, 刘凤林. 全腹腔镜保留贲门胃底胃次全切除术治疗中上部胃癌的疗效及安全性[J]. 北京大学学报(医学版), 2026, 58(2): 301-306.
[8] 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报(医学版), 2026, 58(2): 399-404.
[9] 李斌, 梁寒. 机器人胃癌根治术:研究进展与实践挑战[J]. 北京大学学报(医学版), 2026, 58(2): 416-422.
[10] 董海峰, 陈恒星, 张常华. 恶性肿瘤中蛋白质乳酸化修饰的研究进展[J]. 北京大学学报(医学版), 2026, 58(2): 423-430.
[11] 李宏杨, 黄涛, 王琳琳. 脂肪肌肉比率与卵巢良性肿瘤风险的关联性[J]. 北京大学学报(医学版), 2026, 58(1): 169-174.
[12] 高若凡, 马天宇, 王润楷, 殷雨辰, 李芮迪, 王丹丹, 夏斌. 细胞膜囊泡递送靶向肿瘤坏死因子-α的小干扰RNA对牙髓干细胞的抗炎作用[J]. 北京大学学报(医学版), 2026, 58(1): 22-29.
[13] 刘艳华, 陆敏, 赵旭阳, 张宽根, 武睿, 梅放, 戴志豪, 由江峰, 裴斐. 肿瘤转移抑制基因LASS2去磷酸化对液泡型ATP酶活性及前列腺癌侵袭性的影响[J]. 北京大学学报(医学版), 2025, 57(6): 1113-1123.
[14] 杨小勇, 张帆, 马潞林, 刘承. 前列腺导管腺癌临床特征及腺外侵犯的影响因素[J]. 北京大学学报(医学版), 2025, 57(5): 956-960.
[15] 宁家昕, 王浩然, 罗书航, 敬吉波, 王建业, 侯惠民, 刘明. 氧化应激相关基因与前列腺癌关系的多组学分析[J]. 北京大学学报(医学版), 2025, 57(4): 633-643.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!